Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(13%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
38%
Ph phase_3
3
38%

Phase Distribution

3

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(5)
Other(1)

Detailed Status

Completed5
Not yet recruiting1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 33 (50.0%)

Trials by Status

not_yet_recruiting113%
recruiting113%
unknown113%
completed563%

Recent Activity

1 active trials
Showing 5 of 8
recruiting

Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity

NCT06967389
completed

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

NCT04572165
completedphase_1

Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

NCT06634927
completedphase_3

Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

NCT06739044
completedphase_3

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

NCT06161844
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06967389

Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity

Recruiting
NCT04572165

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

Completed
NCT06634927Phase 1

Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

Completed
NCT06739044Phase 3

Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

Completed
NCT06161844Phase 3

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

Completed
NCT07046273Phase 3

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

Not Yet Recruiting
NCT06497049Phase 1

Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.

Completed
NCT04702516Phase 1

The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8